Onkologie. 2020:14(3):110-113 | DOI: 10.36290/xon.2020.021

Current perspective on diagnosis and treatment of primary central nervous system lymphomas

Andrea Jirkuvová, Vít Procházka, Aleš Obr
Hemato-onkologická klinika Lékařské fakulty Univerzity Palackého v Olomouci a Fakultní nemocnice Olomouc

Primary central nervous system lymphoma is one of extranodal lymphomas with primary aggressive clinical behaviour. It affects brain, spinal cord, leptomeninges and eye. Standard of treatment is induction with chemotherapy including high-dose methotrexate and subsequent consolidation with autologous stem cell transplant or whole-brain radiotherapy. Due to increased incidence in patients older than 60 years with regard to toxicity risks, including cognitive deficit, individualized therapy is necessary. New findings in pathophysiology at molecular level of this lymphoma subtype bring new options with targeted treatment.

Keywords: primary central nervous system lymphoma, methotrexate, whole-brain radiotherapy, autologous stem cell transplant.

Published: June 2, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jirkuvová A, Procházka V, Obr A. Current perspective on diagnosis and treatment of primary central nervous system lymphomas. Onkologie. 2020;14(3):110-113. doi: 10.36290/xon.2020.021.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Shiels MS, Pfeiffer RM, Besson C, et al. Trends in primary central nervous system lymphoma incidence and survival in the U.S. British Journal of Haematology [online]. 2016; 174(3): 417-424 [cit. 2020-01-27]. doi: 10.1111/bjh.14073 Go to original source... Go to PubMed...
    2. Belada D, Trněný M, et al. Diagnostické a léčebné postupy u nemocných s maligními lymfomy, X. vydání, (8. tištěné, doplněné a přepracované vydání), srpen 2018, Hradec Králové, HK CREDIT s.r.o. [cit. 2020-02-25]. Dostupné z: https://www.lymphoma.cz/_uploads/attachments/KLS_guidelines_10_2018_3.pdf.
    3. Batchelor, Tracy T, 2019. Primary central nervous system lymphoma: A curable disease. Hematological Oncology [online]. 37(S1), 15-18 [cit. 2020-02-28]. doi: 10.1002/hon.2598. Go to original source... Go to PubMed...
    4. Nakamura T, Tateishi K, Niwa T, et al. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathology and Applied Neurobiology [online]. 2016; 42(3): 279-290 [cit. 2020-03-01]. doi: 10.1111/nan.12259. Go to original source... Go to PubMed...
    5. Malikova H, Koubska E, Weichet J, Klener J, Rulseh A, Liscak R, Vojtech Z. Can morphological MRI differentiate between primary central nervous system lymphoma and glioblastoma? Cancer Imaging [online]. 2016, 16(1) [cit. 2020-03-20]. doi: 10.1186/s40644-016-0098-9 Go to original source... Go to PubMed...
    6. LIU CJn, Lin SY, Yang CF, et al. 2020. A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma. Cancer Medicine [online]. [cit. 2020-03-01]. doi: 10.1002/cam4.2872. Go to original source... Go to PubMed...
    7. Schmitt AM, Herbrand AK, Fox CP, et al. Rituximab in primary central nervous system lymphoma - A systematic review and meta-analysis. Hematological Oncology [online]. 2019; 37(5): 548-557 [cit. 2020-01-27]. doi: 10.1002/hon.2666. Go to original source... Go to PubMed...
    8. Mocikova H, Pytlik R, Sykorova A, et al. Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry. Leukemia & Lymphoma [online]. 2016; 57(12): 2777-2783 [cit. 2020-03-20]. doi: 10.3109/10428194.2016.1167203. Go to original source... Go to PubMed...
    9. Alnahhas I, Jawish M, Alsawas M, Zukas A, Prokop L, Murad MH, Malkin M. Autologous Stem-Cell Transplantation for Primary Central Nervous System Lymphoma: Systematic Review and Meta-analysis. Clinical Lymphoma Myeloma and Leukemia [online]. 2019; 19(3): e129-e141 [cit. 2020-03-01]. doi: 10.1016/j.clml.2018.11.018. Go to original source... Go to PubMed...
    10. Seidel S, Schlegel U. Have treatment protocols for primary CNS lymphoma advanced in the past 10 years. Expert Review of Anticancer Therapy [online]. 2019; 19(10): 909-915 [cit. 2020-03-01]. doi: 10.1080/14737140.2019.1677157. Go to original source... Go to PubMed...
    11. Correa DD, Braun E, Kryza-Lacombe M, et al. Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation. Journal of Neuro-Oncology [online]. 2019; 144(3): 553-562 [cit. 2020-01-27]. doi: 10.1007/s11060-019-03257-1. Go to original source... Go to PubMed...
    12. Soussain C, Choquet S, Blonski M, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. European Journal of Cancer [online]. 2019; 117: 121-130 [cit. 2020-01-27]. doi: 10.1016/j.ejca.2019.05.024. Go to original source... Go to PubMed...
    13. Ghesquieres H, Chevrier M, Laadhari M, et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA). Annals of Oncology [online]. 2019; 30(4): 621-628 [cit. 2020-01-27]. doi: 10.1093/annonc/mdz032. Go to original source... Go to PubMed...
    14. Tun HW, Johnston PB, Deangelis LM, et al. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. Blood [online]. 2018; 132(21): 2240-2248 [cit. 2020-01-27]. doi: 10.1182/blood-2018-02-835496. Go to original source... Go to PubMed...
    15. Ferreri, Andrés JM, Holdhoff M, Nayak L, Rubenstein JL. Evolving Treatments for Primary Central Nervous System Lymphoma. American Society of Clinical Oncology Educational Book [online]. 2019; (39): 454-466 [cit. 2020-01-27]. doi: 10.1200/EDBK_242547. Go to original source... Go to PubMed...
    16. Grommes C, Nayak L, Tun HW, Batchelor TT. Introduction of novel agents in the treatment of primary CNS lymphoma. Neuro-Oncology [online]. 2019; 21(3): 306-313 [cit. 2020-03-03]. doi: 10.1093/neuonc/noy193. Go to original source... Go to PubMed...
    17. Nayak L, Iwamoto FM, Lacasce A, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood [online]. 2017; 129(23): 3071-3073 [cit. 2020-03-11]. doi: 10.1182/blood-2017-01-764209. Go to original source... Go to PubMed...
    18. Ferreri, Andrés JM, Calimeri T, Conte GM, et al. R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma. Blood [online]. 2019; 134(3): 252-262 [cit. 2020-01-27]. doi 10.1182/blood.2019000633. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.